Ascendis Pharma A/S logo

ASND

Ascendis Pharma A/S

$119.5

Earnings Summary

Revenue
$10.52Mn
Net Profits
$-31.98Mn
Net Profit Margins
-304.12%

Highlights

Revenue:

Ascendis Pharma A/S’s revenue jumped 3655.36% since last year same period to $10.52Mn in the Q4 2018. On a quarterly growth basis, Ascendis Pharma A/S has generated 52475% jump in its revenue since last 3-months.

Net Profits:

Ascendis Pharma A/S’s net profit jumped 6.43% since last year same period to $-31.98Mn in the Q4 2018. On a quarterly growth basis, Ascendis Pharma A/S has generated 5.86% jump in its net profits since last 3-months.

Net Profit Margins:

Ascendis Pharma A/S’s net profit margin jumped 97.51% since last year same period to -304.12% in the Q4 2018. On a quarterly growth basis, Ascendis Pharma A/S has generated 99.82% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ascendis Pharma A/S post its latest quarter earnings

EPS Estimate Current Year
-2.6

Highlights

EPS Estimate Current Year:

Ascendis Pharma A/S’s earning per share (EPS) estimates for the current year stand at -2.6.

Key Ratios

Key ratios of the Ascendis Pharma A/S post its Q2 2022 earnings

Earning Per Share (EPS)
-1.46
Return on Assets (ROA)
-0.27
Return on Equity (ROE)
-0.67

Highlights

Earning Per Share (EPS):

Ascendis Pharma A/S’s earning per share (EPS) jumped 41.6% since last year same period to -1.46 in the Q2 2022. This indicates that the Ascendis Pharma A/S has generated 41.6% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S’s return on assets (ROA) stands at -0.27.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S’s return on equity (ROE) stands at -0.67.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-2.06
-2.21
-7.28%
2022-06-30
-2.16
-1.46
32.41%

Company Information

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Organisation
Ascendis Pharma A/S
Headquarters
Tuborg Boulevard 12, Hellerup, Denmark, 2900
Employees
639
Industry
Health Technology
CEO
Jan Moeller Mikkelsen

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*